A
Artur Racewicz
Publications - 5
Citations - 876
Artur Racewicz is an academic researcher. The author has contributed to research in topics: Randomized controlled trial & Placebo-controlled study. The author has an hindex of 5, co-authored 5 publications receiving 748 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))
Paul Emery,A. Deodhar,William F. C. Rigby,John D. Isaacs,B. Combe,Artur Racewicz,Kevin Latinis,Carlos Abud-Mendoza,Leszek Szczepanski,R. A. Roschmann,A. Chen,Gillian Armstrong,Wendy Douglass,H. Tyrrell +13 more
TL;DR: Rituximab (at 2×500 mg and 2×1000 mg) plus MTX significantly improved clinical outcomes at week 24, which were further improved by week 48, and no significant differences in either clinical or safety outcomes were apparent between the rituxIMab doses.
Journal ArticleDOI
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
Désirée van der Heijde,James Cheng-Chung Wei,Maxime Dougados,Philip J. Mease,Atul Deodhar,Walter P. Maksymowych,Filip Van den Bosch,Joachim Sieper,Tetsuya Tomita,Robert Landewé,Fangyi Zhao,Eswar Krishnan,David H. Adams,Beth A. Pangallo,Hilde Carlier,Melvin Churchill,Kathleen P. Flint,Geoffrey Gladstein,Maria Greenwald,Mary P. Howell,Akgun Ince,Jeffrey L. Kaine,Daksha Mehta,Eric A. Peters,Roel Querubin,John D. Reveille,Richard Roseff,Roger J. Diegel,Christine Thai,Louis Bessette,Frederic Morin,Proton Rahman,Aaron Alejandro Barrera Rodriguez,Fidencio Cons-Molina,Sergio Duran Barragan,Cassandra M. Skinner,Cesar Francisco Pacheco Tena,Cesar Ricardo Ramos Remus,Juan Cruz Rizo Rodriguez,Seung-Jae Hong,Yeon-Ah Lee,Ji Hyeon Ju,Seong Wook Kang,Tae-Hwan Kim,Chang Keun Lee,Eun Bong Lee,Sang-Heon Lee,Min Chan Park,Kichul Shin,Sang-Hoon Lee,Hung-An Chen,Ying-Chou Chen,Song-Chou Hsieh,Joung-Liang Lan,Zdenek Dvorak,Radka Moravcova,Martina Malcova,Yoshinori Taniguchi,Mitsumasa Kishimoto,Kurisu Tada,Hiroaki Dobashi,Kentaro Inui,Yukitaka Ueki,Yoshifuji Matsumoto,Yoshinobu Koyama,Kazuhiro Hatta,Tatsuya Atsumi,Hitoshi Goto,Kiyoshi Matsui,Yuya Takakubo,Gunther Neeck,Denis Poddubnyy,Andrea Rubbert-Roth,Malgorzata Szymanska,Tomasz Blicharski,Anna Dudek,Artur Racewicz,Rafal Wojciechowski,Marleen G H van de Sande,Ed Griep,Michael T. Nurmohamed,Galina Matsievskaya,Evgeniya Shmidt,Marina Stanislav,Sergey Yakushin,Olga Ershova,A P Rebrov,Tibor Balazs,Regina Cseuz,E. Drescher,Gyula Poor +90 more
TL;DR: Each dosing regimen of ixekizumab was superior to placebo for improving radiographic axial spondyloarthritis signs and symptoms in patients not previously treated with bDMARDs; the safety profile was consistent with previous indications of IXekzumab.
Journal ArticleDOI
A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study
Dae Hyun Yoo,Artur Racewicz,Jan Brzezicki,Roman Yatsyshyn,Edgardo Tobias Arteaga,Asta Baranauskaite,Carlos Abud-Mendoza,Sandra V. Navarra,Vladimir Kadinov,Irmgadt Goecke Sariego,Seung Suh Hong,Sung Young Lee,Won Park +12 more
TL;DR: CT-P13 and RP were comparable in terms of efficacy, immunogenicity, safety, pharmacokinetics (PK) and pharmacodynamics (PD) up to week 54 in patients with active rheumatoid arthritis.
Journal ArticleDOI
Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.
Atul Deodhar,A.B. Gottlieb,Wolf-Henning Boehncke,Wolf-Henning Boehncke,Bin Dong,Y. Wang,Yanli Zhuang,William Barchuk,X. L. Xu,Elizabeth C. Hsia,Jacob A. Aelion,Juan Amarelo-Ramos,Alejandro Balsa,Florian Berghea,Jan Brzezicki,Michael Burnette,Scott Fretzin,S. García-Carazo,Geoffrey Gladstein,Juan J. Gomez-Reino,Melinda Gooderham,Carlos González-Fernández,Alice B. Gottlieb,Jordi Gratacós,Derek Haaland,Rima Kamalova,Piotr Leszczyński,Emilio Martín-Mola,Alexey Maslyansky,F. Navarro,Daniela Opris,Kim A. Papp,Yuriy Perlamutrov,Sandra Philipp,Artur Racewicz,A P Rebrov,Maria Rell-Bakalarska,David Rosmarin,Andrea Rubbert-Roth,William Shergy,Ivan Shirinsky,Dmitry Sonin,Marina Stanislav,Alexey Sukharev,Vadim Temnikov,Irina Vinogradova,Paul Waytz,Vladimir Yakushevich +47 more
TL;DR: The proportion of patients with at least 20% improvement at week 24 in signs and symptoms of psoriatic arthritis according to American College of Rheumatology criteria (ACR20) in the modified intention-to-treat population was found.
Journal ArticleDOI
OP0068 A Phase 3 Randomised Controlled Trial to Compare CT-P13 with Infliximab in Patients with Active Rheumatoid Arthritis: 54 Week Results from the Planetra Study
Dae-Hyun Yoo,Artur Racewicz,Jan Brzezicki,Roman Yatsyshyn,E. Tobias Arteaga,Asta Baranauskaite,Carlos Abud-Mendoza,Sandra V. Navarra,R. Eullaran,Vladimir Kadinov,I. Goecke Sariego,P. Byrne,Won Park,Sang Joon Lee,HoUng Kim,Ulf Müller-Ladner +15 more
TL;DR: CT-P13 was well tolerated with a safety profile comparable to that of INX up to week 54, and a randomized, double-blind, phase 3 study demonstrates clinical equivalence of CT-P 13 to infliximab when co-administered with methotrexate in patients with active rheumatoid arthritis.